Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats

Biological and Pharmaceutical Bulletin

Volumn 20, Issue 4, 1997, Pages 386-391

  Tokunaga, Jin ^a   Kobayashi, Mie ^a   Kitagawa, Akira ^a   Nakamura, Chizuko ^a   Arimori, Kazuhiko ^a   Nakano, Masahiro ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

betamipron; cisplatin; N benzoyl alanine; nephrotoxicity; pharmacokinetics

Indexed keywords

BETAMIPRON; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; MALE; NEPHROTOXICITY; NONHUMAN; RAT; TOXICITY TESTING; WALKER CARCINOMA;

EID: 0030909145     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.20.386     Document Type: Article

References (21)

1. Hayashi T., Watanabe Y., Kumano K., Kitayama R., Muratani T., Yasuda T., Saikawa I., Katahira J., Kumada T., Shimizu K., Antimicrob. Agents Chemother., 33, 513-518 (1989).
2. Hori R., Ishikawa Y., Takano M., Okano T., Kitazawa S., Inui K., Biochem. Pharmacol., 31, 2267-2272 (1982).
3. Ross D. A., Gale G. R., Cancer Treat. Rep., 63, 781-787 (1979).
4. Jacobs C., Coleman C. N., Rich L., Hirst K., Weiner M. W., Cancer Res., 44, 3632-3635 (1984).
5. Jacobs C., Kaubisch S., Halsey J., Cancer, 67, 1518-1524 (1991).
6. Naganuma H., Tokiwa H., Hirouchi Y., Kawahara Y., Fukushige J., Fukami M., Hirota K., Muramatsu S., Takahagi H., Inui K., Tanigawara Y., Yasuhara M., Hori R., Kuwahara S., Chemotherapy, 39 (S-3), 166-177 (1991).
7. Naganuma H., Hirouchi Y., Kawahara Y., Inui K., Tanigawara Y., Yasuhara M., Hori R., Kuwahara S., Chemotherapy, 39 (S-3), 178-189 (1991).
8. Tokunaga J., Kobayashi M., Nakamura C., Kitagawa A., Arimori K., Nakano M., Renal Fail., 18, 225-240 (1996).
9. Tokunaga J., Kobayashi M., Kitagawa A., Nakamura C., Arimori K., Nakano M., Biol. Pharm. Bull., 19, 1451-1456 (1996).
10. Aamdal S., Fodstad O., Pihl A., Cancer Treat. Rev., 14, 389-395 (1987).
11. Sugiyama K., Yokota M., Ueda H., Ichio Y., J. Med. Pharm. Soc. Wakan-Yaku, 10, 76-85 (1993).
12. Arimori K., Deshimaru M., Furukawa E., Nakano M., J. Pharm. Pharmacol., 44, 977-980 (1992).
13. Prestayko A. W., D'Aoust J. C., Issell B. F., Crooke S. T., Cancer Treat. Rev., 6, 17-39 (1979).
14. Durant J. R., "Cisplatin, Current Status and New Developments," ed. by Prestayko A. W., Crooke S. T., Carter S. K., Academic Press, New York, 1980, pp. 317-321.
15. Irie T., Hashimoto Y., Irie A., Ishibashi M., Miyazaki H., Machida H., Karasawa Y., Nakamori K., Iyakuhin Kenkyu, 14, 384-410 (1983).
16. Daley-Yates P. T., McBrien D. C. H., Biochem. Pharmacol., 31, 2243-2246 (1982).
17. Daley-Yates P. T., McBrien D. C. H., Biochem. Pharmacol., 34, 1423-1428 (1985).
18. Kiyozumi M., Inoue T., Kojima S., Hidaka S., Tsuruoka M., Toxicology, 67, 41-51 (1991).
19. Takahagi H., Matsushita Y., Hirota T., Shigeta A., Muramatsu S., Nakajima E., Kawahara Y., Chemotherapy, 39 (S-3), 206-226 (1991).
20. DeSimone P. A., Yancey R. S., Coupal J. J., Butts J. D., Hoeschel J. D., Cancer Treat. Rep., 63, 951-960 (1979).
21. Howell S. B., Taetle R., Cancer Treat. Rep., 64, 611-616 (1980).